By Darren Incorvaia
Publication Date: 2026-02-27 18:37:00
On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a $1 trillion valuation teaming up with a tech firm that has ridden the AI wave to a record-setting $5 trillion valuation of its own—a Wall Street supergroup, a la Cream, Audioslave or boygenius.
But Lilly leaders told Fierce Biotech that a baser instinct is driving the drug giant’s decision to invest big in Nvidia and AI: anxiety.
“We’re trying to escape the traditional pharma industry life cycle,” Diogo Rau, Lilly’s chief information and digital officer, told Fierce. “This industry is so bizarre compared to other industries, with these huge peaks and these really deep troughs that span decades.”
With Lilly currently climbing to perhaps the highest peak in pharma history thanks to the success of its diabetes and weight loss drug tirzepitide, Rau wants to avoid the comedown.
“What can you do to break out of that cycle?” Rau asked. “It’s probably the thing that I’m the most concerned about, for the long term.”
It’s here where Nvidia—and the AI applications its computing power enables—come in.
On Wednesday, Lilly leaders including Rau and Chief AI Officer Thomas Fuchs, Ph.D., cut the ribbon on a new Nvidia supercomputer, named LillyPod, that the Big Pharma believes to be the most powerful in the industry.
After first announcing the supercomputer in October, Lilly and Nvidia